Abstract
Successful gene therapy has been limited by safe and efficient delivery of nucleic acid to the target cells. Poly (d,l-lactide-co-glycolide) (PLGA) nanoparticles (NPs) are able to deliver drugs and genes efficiently. This formulation has several advantages in comparison with other formulations including improvement in solubility, stability, controlling of degradation and release of the entrapped agents. For application of PLGA as a gene carrier, there exist many challenges. PLGA NPs could protect the encapsulated DNA from in vivo degradation but the DNA release is slow and the negative charge acts as a barrier to DNA incorporation and delivery. Also, during the preparation process, DNA could be exposed to high shear stress and organic solvents which could result in its inactivation. Moreover, PLGA NPs could be modified with different agents to reduce cytotoxicity, to enhance delivery efficiency and to target specific tissues/cells. This review summarizes different methods used for the preparation of PLGA NPs as gene carriers and recent strategies for the modification of PLGA particles applied in gene therapy.
Keywords: PLGA, gene delivery, encapsulation, modification, nanoparticles.
Current Medicinal Chemistry
Title:Current Strategies in the Modification of PLGA-based Gene Delivery System
Volume: 24 Issue: 7
Author(s): Mohammad Ramezani, Mahboubeh Ebrahimian and Maryam Hashemi*
Affiliation:
- Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, P.O. Box: 91775-1365, Mashhad,Iran
Keywords: PLGA, gene delivery, encapsulation, modification, nanoparticles.
Abstract: Successful gene therapy has been limited by safe and efficient delivery of nucleic acid to the target cells. Poly (d,l-lactide-co-glycolide) (PLGA) nanoparticles (NPs) are able to deliver drugs and genes efficiently. This formulation has several advantages in comparison with other formulations including improvement in solubility, stability, controlling of degradation and release of the entrapped agents. For application of PLGA as a gene carrier, there exist many challenges. PLGA NPs could protect the encapsulated DNA from in vivo degradation but the DNA release is slow and the negative charge acts as a barrier to DNA incorporation and delivery. Also, during the preparation process, DNA could be exposed to high shear stress and organic solvents which could result in its inactivation. Moreover, PLGA NPs could be modified with different agents to reduce cytotoxicity, to enhance delivery efficiency and to target specific tissues/cells. This review summarizes different methods used for the preparation of PLGA NPs as gene carriers and recent strategies for the modification of PLGA particles applied in gene therapy.
Export Options
About this article
Cite this article as:
Ramezani Mohammad, Ebrahimian Mahboubeh and Hashemi Maryam*, Current Strategies in the Modification of PLGA-based Gene Delivery System, Current Medicinal Chemistry 2017; 24 (7) . https://dx.doi.org/10.2174/0929867324666161205130416
DOI https://dx.doi.org/10.2174/0929867324666161205130416 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Wheel of Fortune – Cyclic Peptides Hit the Mimetic Jackpot: Current Syntheses, Uses and Roles for Cyclic Peptide Mimetics
Current Chemical Biology Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice?
Current Medicinal Chemistry Prediction of Essential Proteins in Prokaryotes by Incorporating Various Physico-chemical Features into the General form of Chou’s Pseudo Amino Acid Composition
Protein & Peptide Letters The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Current Pharmaceutical Design vHTS, 3-D Pharmacophore, QSAR and Molecular Docking Studies for the Identification of Phyto-derived ATP-Competitive Inhibitors of the BCR-ABL Kinase Domain
Current Drug Discovery Technologies Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells?
Recent Patents on Anti-Cancer Drug Discovery PDE-5 Inhibitors for BPH-Associated LUTS
Current Drug Targets Integrins and Cancer: Gene Expression, Epigenetics and Metastasis
Current Genomics Low Molecular Weight Heparins as Antineoplastic Agents
Recent Patents on Anti-Cancer Drug Discovery Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Current Drug Targets New Tubulin Polymerization Inhibitor Derived from Thalidomide: Implications for Anti-Myeloma Therapy
Current Medicinal Chemistry Editorial [Hot Topic: Molecular Tools in Cancer Diagnosis and Therapy Guest Editor: Riyaz Basha]
Current Medicinal Chemistry Stem Cell and Idiopathic Pulmonary Fibrosis: Mechanisms and Treatment
Current Stem Cell Research & Therapy Recent Evidence on the Role of Dietary PUFAs in Cancer Development and Prevention
Current Medicinal Chemistry Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Toxic Epidermal Necrolysis and Antifolate Drugs in Cancer Chemotherapy
Current Drug Safety Antimicrobial Activity of New 2-Thioxo-benzo[g]quinazolin-4(3H)-one Derivatives
Medicinal Chemistry Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance
Mini-Reviews in Medicinal Chemistry Graphical Abstracts
Anti-Cancer Agents in Medicinal Chemistry Underexpression of miR-486-5p but not Overexpression of miR-155 is Associated with Lung Cancer Stages
MicroRNA